Dr. Suma P. Satti
Claim this profileOchsner Medical Center Jefferson
Studies Lung Cancer
Studies Cancer
6 reported clinical trials
17 drugs studied
Area of expertise
1Lung Cancer
Stage III
Stage I
Stage II
2Cancer
Stage III
BRCA1 positive
BRCA2 positive
Affiliated Hospitals
Clinical Trials Suma P. Satti is currently running
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria
Chemotherapy + Bevacizumab + Atezolizumab
for Colorectal Cancer
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Recruiting2 awards Phase 31 criteria
More about Suma P. Satti
Clinical Trial Related4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Suma P. Satti has experience with
- Atezolizumab
- Carboplatin
- Durvalumab
- Nivolumab
- Ipilimumab
- Paclitaxel
Breakdown of trials Suma P. Satti has run
Lung Cancer
Adenocarcinoma
Colorectal Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Suma P. Satti specialize in?
Suma P. Satti focuses on Lung Cancer and Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are Stage I.
Is Suma P. Satti currently recruiting for clinical trials?
Yes, Suma P. Satti is currently recruiting for 2 clinical trials in New Orleans Louisiana. If you're interested in participating, you should apply.
Are there any treatments that Suma P. Satti has studied deeply?
Yes, Suma P. Satti has studied treatments such as Atezolizumab, Carboplatin, Durvalumab.
What is the best way to schedule an appointment with Suma P. Satti?
Apply for one of the trials that Suma P. Satti is conducting.
What is the office address of Suma P. Satti?
The office of Suma P. Satti is located at: Ochsner Medical Center Jefferson, New Orleans, Louisiana 70121 United States. This is the address for their practice at the Ochsner Medical Center Jefferson.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.